MX2016001896A - Derivados de amida como agonistas del receptor del ácido lisofosfatídico. - Google Patents
Derivados de amida como agonistas del receptor del ácido lisofosfatídico.Info
- Publication number
- MX2016001896A MX2016001896A MX2016001896A MX2016001896A MX2016001896A MX 2016001896 A MX2016001896 A MX 2016001896A MX 2016001896 A MX2016001896 A MX 2016001896A MX 2016001896 A MX2016001896 A MX 2016001896A MX 2016001896 A MX2016001896 A MX 2016001896A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonists
- acid receptor
- amide derivatives
- lysophosphatidic acid
- formula
- Prior art date
Links
- 229940123977 Lysophosphatidic acid receptor antagonist Drugs 0.000 title 1
- 150000001408 amides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1314926.5A GB201314926D0 (en) | 2013-08-20 | 2013-08-20 | Novel Compounds |
| PCT/GB2014/052558 WO2015025164A1 (en) | 2013-08-20 | 2014-08-20 | Amide derivatives as lysophosphatidic acid receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016001896A true MX2016001896A (es) | 2016-05-26 |
Family
ID=49301993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001896A MX2016001896A (es) | 2013-08-20 | 2014-08-20 | Derivados de amida como agonistas del receptor del ácido lisofosfatídico. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10100018B2 (enExample) |
| EP (1) | EP3036215A1 (enExample) |
| JP (1) | JP6422974B2 (enExample) |
| KR (1) | KR20160045797A (enExample) |
| CN (1) | CN105473548B (enExample) |
| AR (1) | AR097403A1 (enExample) |
| AU (1) | AU2014310404B2 (enExample) |
| CA (1) | CA2921742A1 (enExample) |
| CL (1) | CL2016000387A1 (enExample) |
| CR (1) | CR20160084A (enExample) |
| EA (1) | EA028818B1 (enExample) |
| GB (1) | GB201314926D0 (enExample) |
| HK (1) | HK1225712A1 (enExample) |
| IL (1) | IL243780A0 (enExample) |
| MA (1) | MA38854B1 (enExample) |
| MX (1) | MX2016001896A (enExample) |
| PE (1) | PE20160284A1 (enExample) |
| PH (1) | PH12016500322A1 (enExample) |
| SG (1) | SG11201601250TA (enExample) |
| TN (1) | TN2016000061A1 (enExample) |
| TW (1) | TW201536722A (enExample) |
| UY (1) | UY35708A (enExample) |
| WO (1) | WO2015025164A1 (enExample) |
| ZA (1) | ZA201600753B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201314926D0 (en) * | 2013-08-20 | 2013-10-02 | Takeda Pharmaceutical | Novel Compounds |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| JP7173350B2 (ja) | 2019-07-30 | 2022-11-16 | 大正製薬株式会社 | Ｌｐａ１受容体を拮抗するウレア化合物 |
| CN114728168B (zh) | 2019-11-15 | 2024-04-09 | 吉利德科学公司 | 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| AU2021282986B2 (en) | 2020-06-03 | 2024-03-07 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| KR20240005892A (ko) | 2021-05-11 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| AU2022405082B2 (en) | 2021-12-08 | 2025-09-25 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2024252334A1 (en) * | 2023-06-06 | 2024-12-12 | Gpcr Therapeutics, Inc. | Gpcr inhibitors and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2707641B1 (fr) * | 1993-07-16 | 1995-08-25 | Fournier Ind & Sante | Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique. |
| ES2239203T3 (es) | 2001-01-31 | 2005-09-16 | Pfizer Products Inc. | Derivados nicotinamida y sus mimeticos como inhibidores de isozimas pde4. |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| TW200400930A (en) * | 2002-06-26 | 2004-01-16 | Ono Pharmaceutical Co | Therapeutic agent for chronic disease |
| EP1553075B1 (en) * | 2002-10-03 | 2013-08-14 | Ono Pharmaceutical Co., Ltd. | Lpa receptor antagonists |
| IN2012DN00754A (enExample) * | 2009-08-04 | 2015-06-19 | Amira Pharmaceuticals Inc | |
| WO2011037192A1 (ja) | 2009-09-25 | 2011-03-31 | アステラス製薬株式会社 | 置換アミド化合物 |
| GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| PH12012500542A1 (en) * | 2010-09-24 | 2012-11-12 | Astellas Pharma Inc | Substituted amide compound |
| US8785442B2 (en) | 2011-01-30 | 2014-07-22 | Curegenix, Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
| EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| GB201314926D0 (en) | 2013-08-20 | 2013-10-02 | Takeda Pharmaceutical | Novel Compounds |
-
2013
- 2013-08-20 GB GBGB1314926.5A patent/GB201314926D0/en not_active Ceased
-
2014
- 2014-08-18 TW TW103128316A patent/TW201536722A/zh unknown
- 2014-08-19 UY UY0001035708A patent/UY35708A/es not_active Application Discontinuation
- 2014-08-20 MA MA38854A patent/MA38854B1/fr unknown
- 2014-08-20 AR ARP140103129A patent/AR097403A1/es unknown
- 2014-08-20 JP JP2016535530A patent/JP6422974B2/ja not_active Expired - Fee Related
- 2014-08-20 US US14/913,135 patent/US10100018B2/en not_active Expired - Fee Related
- 2014-08-20 SG SG11201601250TA patent/SG11201601250TA/en unknown
- 2014-08-20 MX MX2016001896A patent/MX2016001896A/es unknown
- 2014-08-20 EA EA201690390A patent/EA028818B1/ru not_active IP Right Cessation
- 2014-08-20 CA CA2921742A patent/CA2921742A1/en not_active Abandoned
- 2014-08-20 TN TN2016000061A patent/TN2016000061A1/en unknown
- 2014-08-20 PE PE2016000269A patent/PE20160284A1/es not_active Application Discontinuation
- 2014-08-20 KR KR1020167007214A patent/KR20160045797A/ko not_active Withdrawn
- 2014-08-20 US US14/463,780 patent/US9464060B2/en not_active Expired - Fee Related
- 2014-08-20 CN CN201480046178.8A patent/CN105473548B/zh not_active Expired - Fee Related
- 2014-08-20 WO PCT/GB2014/052558 patent/WO2015025164A1/en not_active Ceased
- 2014-08-20 EP EP14756117.9A patent/EP3036215A1/en not_active Withdrawn
- 2014-08-20 HK HK16113982.5A patent/HK1225712A1/zh unknown
- 2014-08-20 AU AU2014310404A patent/AU2014310404B2/en not_active Expired - Fee Related
-
2016
- 2016-01-26 IL IL243780A patent/IL243780A0/en unknown
- 2016-02-03 ZA ZA2016/00753A patent/ZA201600753B/en unknown
- 2016-02-18 PH PH12016500322A patent/PH12016500322A1/en unknown
- 2016-02-19 CL CL2016000387A patent/CL2016000387A1/es unknown
- 2016-02-19 CR CR20160084A patent/CR20160084A/es unknown
-
2018
- 2018-08-20 US US15/999,570 patent/US20190010129A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA028818B1 (ru) | 2018-01-31 |
| CA2921742A1 (en) | 2015-02-26 |
| WO2015025164A1 (en) | 2015-02-26 |
| EP3036215A1 (en) | 2016-06-29 |
| AR097403A1 (es) | 2016-03-09 |
| CL2016000387A1 (es) | 2016-12-16 |
| PH12016500322A1 (en) | 2016-05-02 |
| US20160207880A1 (en) | 2016-07-21 |
| GB201314926D0 (en) | 2013-10-02 |
| US10100018B2 (en) | 2018-10-16 |
| KR20160045797A (ko) | 2016-04-27 |
| US9464060B2 (en) | 2016-10-11 |
| SG11201601250TA (en) | 2016-03-30 |
| MA38854B1 (fr) | 2018-05-31 |
| US20150057298A1 (en) | 2015-02-26 |
| CN105473548A (zh) | 2016-04-06 |
| PE20160284A1 (es) | 2016-04-27 |
| EA201690390A1 (ru) | 2016-08-31 |
| MA38854A1 (fr) | 2017-07-31 |
| JP2016528274A (ja) | 2016-09-15 |
| CR20160084A (es) | 2016-05-27 |
| ZA201600753B (en) | 2019-07-31 |
| TW201536722A (zh) | 2015-10-01 |
| HK1225712A1 (zh) | 2017-09-15 |
| AU2014310404B2 (en) | 2018-07-12 |
| CN105473548B (zh) | 2018-03-23 |
| AU2014310404A1 (en) | 2016-03-10 |
| IL243780A0 (en) | 2016-04-21 |
| UY35708A (es) | 2014-12-31 |
| JP6422974B2 (ja) | 2018-11-14 |
| TN2016000061A1 (en) | 2017-07-05 |
| US20190010129A1 (en) | 2019-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500322A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| MY169986A (en) | Benzimidazole-proline derivatives | |
| PH12017500281A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| MY185221A (en) | New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| PH12015501996A1 (en) | Heterocyclic compounds and uses thereof | |
| PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| GB201209587D0 (en) | Therapeutic compounds | |
| TN2017000384A1 (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors. | |
| MX2016012451A (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina. | |
| PH12014501415A1 (en) | Heterocyclic amide derivatives as p2x7 receptor antagonists | |
| PH12017501280B1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
| MX367772B (es) | Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk. | |
| PH12015502632A1 (en) | Cxcr7 receptor modulators | |
| MX2017009292A (es) | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. | |
| PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
| HK1219723A1 (zh) | 作为前动力蛋白受体调节剂的派啶和氮杂䓬衍生物 | |
| UA112586C2 (uk) | Похідні бензімідазолпроліну | |
| TN2014000077A1 (en) | Pyridazinone compounds and their use as daao inhibitors |